TCRX (STOCKS)
TScan Therapeutics, Inc. Common Stock
$1.039100
-0.010900 (-1.04%)
Prev close: $1.050000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Gavin MacBeath
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $58.04M
- Employees
- 210
- P/E (TTM)
- -1.05
- P/B (TTM)
- 0.49
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
7
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.18 | $-0.25 | +0.0660 | +26.83% |
|
Sep 2025 (Q3)
|
$-0.28 | $-0.30 | +0.0212 | +7.04% |
|
Jun 2025 (Q2)
|
$-0.28 | $-0.29 | +0.0062 | +2.17% |
|
Mar 2025 (Q1)
|
$-0.26 | $-0.29 | +0.0317 | +10.87% |
Financial Statements
| Revenues | $10.33M |
| Benefits Costs and Expenses | $140.09M |
| Costs And Expenses | $140.09M |
| Operating Expenses | $146.14M |
| Depreciation and Amortization | $2.90M |
| Research and Development | $114.15M |
| Other Operating Expenses | $29.09M |
| Operating Income/Loss | -$135.81M |
| Income/Loss From Continuing Operations After Tax | -$129.77M |
| Income/Loss From Continuing Operations Before Tax | -$129.77M |
| Income Tax Expense/Benefit | $0.00 |
| Interest Expense, Operating | $2.77M |
| Net Income/Loss | -$129.77M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$129.77M |
| Net Income/Loss Available To Common Stockholders, Basic | -$129.77M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.00 |
| Diluted Earnings Per Share | -$1.00 |
| Basic Average Shares | 129,777,415 |
| Diluted Average Shares | 129,777,415 |
| Assets | $228.79M |
| Current Assets | $157.21M |
| Noncurrent Assets | $71.58M |
| Fixed Assets | $8.71M |
| Other Non-current Assets | $62.88M |
| Liabilities | $105.67M |
| Current Liabilities | $18.70M |
| Accounts Payable | $1.24M |
| Wages | $4.15M |
| Other Current Liabilities | $13.31M |
| Noncurrent Liabilities | $86.97M |
| Long-term Debt | $32.53M |
| Other Non-current Liabilities | $54.44M |
| Equity | $123.12M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $123.12M |
| Liabilities And Equity | $228.79M |
| Net Cash Flow From Operating Activities | -$135.32M |
| Net Cash Flow From Operating Activities, Continuing | -$135.32M |
| Net Cash Flow From Investing Activities | $109.37M |
| Net Cash Flow From Investing Activities, Continuing | $109.37M |
| Net Cash Flow From Financing Activities | -$336.00K |
| Net Cash Flow From Financing Activities, Continuing | -$336.00K |
| Net Cash Flow | -$26.28M |
| Net Cash Flow, Continuing | -$26.28M |
| Comprehensive Income/Loss | -$129.82M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$129.82M |
| Other Comprehensive Income/Loss | -$51.00K |